RxDoctor Payments Data

Daniel Knorpp, DO

Family Medicine · Eagle, IDNPI 1538214184

Payments from drug & device makers

$1,277in general payments, 2019–2025

Across 45 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$236
  • Dexcom, Inc.$155
  • AstraZeneca$154
  • Lilly USA, LLC$138
  • Novo Nordisk$133
  • GSK$109
  • plus $353 from 10 others

What the payments were for

  • Food & beverage$1,277100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,277 in reported general payments places this provider in the 75th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$66,934
Medicare patients
243
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$71,619
MounjaroTirzepatide62$67,014
OzempicSemaglutide29$40,133
RybelsusSemaglutide32$38,409
JardianceEmpagliflozin26$25,558
FarxigaDapagliflozin Propanediol21$19,893
JanuviaSitagliptin Phosphate11$17,050
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$11,593
LinzessLinaclotide12$6,430
Admelog SolostarInsulin Lispro24$6,124
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,634
Atorvastatin Calcium474$4,504
Levothyroxine Sodium378$3,952
Gabapentin198$3,200
Rosuvastatin Calcium210$2,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$133$78,54261 claims
PfizerEliquis$39$71,61966 claims
Lilly USA, LLCMounjaro$138$67,01462 claims
AstraZenecaFarxiga$154$19,89321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 803 family medicine providers in Idaho.

Other family medicine in Eagle

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →